A Nano‐Interception Strategy for Chronic Heart Failure: Prussian Blue Nanoparticles Disrupt Fibroblast‐Immune Communication via CCL2 Sequestration
macrophages without systemic immunosuppression. Supported by scalable production (> 100 g/batch), long-term stability, and biosafety, this work establishes a cell communication-targeting nanomedicine strategy for network-driven diseases like HF.
Authors
- Hongyu Yan
- Guowei Zeng (ORCID: https://orcid.org/0000-0003-1530-3883)
- X Q Zhang
- Kai Luo (ORCID: https://orcid.org/0000-0003-4023-7259)
- Bozhong Shi (ORCID: https://orcid.org/0000-0003-3794-6601)
- Cong Li (ORCID: https://orcid.org/0000-0002-8694-4111)
- Jinghao Zheng (ORCID: https://orcid.org/0000-0001-7459-6730)
- Lingyan Cheng
- Zijie Zhou (ORCID: https://orcid.org/0000-0002-6525-2423)
- Xiaomin He (ORCID: https://orcid.org/0000-0002-6079-1014)
- Rongrong Wu
- Haoyu Li
- Bo Chen
- Xiaojun Cai (ORCID: https://orcid.org/0000-0002-2896-7366)
- Gao Wei
- Longming Huang
Institutions
- Shanghai Children's Medical Center (CN)
- Shanghai Sixth People's Hospital (CN)
Publication Details
- Journal
- Advanced Materials
- Published
- 2026-04-24
- DOI
- https://doi.org/10.1002/adma.202520209
- Primary Topic
- Cardiac Fibrosis and Remodeling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities